SG Americas Securities LLC Buys 15,342 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

SG Americas Securities LLC increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 93.8% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 31,704 shares of the medical research company’s stock after purchasing an additional 15,342 shares during the period. SG Americas Securities LLC’s holdings in Charles River Laboratories International were worth $6,549,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of CRL. Headlands Technologies LLC bought a new position in Charles River Laboratories International in the first quarter valued at about $41,000. VisionPoint Advisory Group LLC grew its stake in Charles River Laboratories International by 45.1% during the fourth quarter. VisionPoint Advisory Group LLC now owns 209 shares of the medical research company’s stock worth $49,000 after purchasing an additional 65 shares during the period. Brown Brothers Harriman & Co. boosted its holdings in Charles River Laboratories International by 76.0% in the fourth quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after acquiring an additional 95 shares in the last quarter. GAMMA Investing LLC bought a new position in Charles River Laboratories International in the fourth quarter worth approximately $62,000. Finally, Concord Wealth Partners boosted its holdings in Charles River Laboratories International by 362.5% in the first quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock worth $70,000 after acquiring an additional 203 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Argus reiterated a “hold” rating on shares of Charles River Laboratories International in a report on Friday, June 28th. TD Cowen reduced their target price on Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating for the company in a research report on Monday, May 13th. UBS Group reduced their target price on Charles River Laboratories International from $290.00 to $240.00 and set a “buy” rating for the company in a research report on Thursday. Evercore ISI dropped their price target on Charles River Laboratories International from $265.00 to $225.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, Mizuho initiated coverage on Charles River Laboratories International in a research note on Friday, June 7th. They set a “neutral” rating and a $235.00 price target for the company. Ten research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $232.79.

Charles River Laboratories International Trading Down 0.5 %

NYSE:CRL traded down $0.96 during mid-day trading on Friday, reaching $200.97. 1,060,174 shares of the company’s stock traded hands, compared to its average volume of 581,319. Charles River Laboratories International, Inc. has a 12-month low of $161.65 and a 12-month high of $275.00. The company has a 50 day moving average price of $214.99 and a 200-day moving average price of $231.28. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.75 and a quick ratio of 1.37. The firm has a market capitalization of $10.35 billion, a price-to-earnings ratio of 23.64, a PEG ratio of 2.32 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, topping the consensus estimate of $2.05 by $0.22. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $997.24 million. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. On average, sell-side analysts predict that Charles River Laboratories International, Inc. will post 10.99 earnings per share for the current year.

Charles River Laboratories International declared that its board has initiated a stock repurchase plan on Wednesday, August 7th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 9.6% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).